Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: A novel mechanism mediating its blockade of osteoclastogenesis

Journal of Cellular Biochemistry

Volumn 112, Issue 11, 2011, Pages 3385-3392

  Cheng, Jing ^a,b   Liu, Jianzhong ^a   Shi, Zhenqi ^a   Xu, Duorong ^b   Luo, Shaokai ^b   Siegal, Gene P ^a   Feng, Xu ^a   Wei, Shi ^a  

^a University of Alabama at Birmingham   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

BONE MARROW MACROPHAGE; IL 4; NFATc1; OSTEOCLAST; RANKL; STAT6

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR ACTIVATED T CELL C1; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT MURINE INTERLEUKIN 4; STAT6 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; CELLS, CULTURED; DNA PRIMERS; GENE EXPRESSION REGULATION; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT6 TRANSCRIPTION FACTOR;

EID: 80055017390     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23269     Document Type: Article

References (33)

1. Abu-Amer Y,. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 107: 1375-1385. (Pubitemid 32522031)
2. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H,. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202: 1261-1269. (Pubitemid 41586956)
3. Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, Susa M,. 2002. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277: 21971-21982. (Pubitemid 34952352)
4. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T,. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114: 475-484. (Pubitemid 39572097)
5. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T,. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277: 41147-41156. (Pubitemid 35215706)
6. Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M,. 2005. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: A possible mechanism for downregulation of osteoclastogenesis. Biochem Biophys Res Commun 329: 839-845. (Pubitemid 40341354)
7. Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA,. 2006. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem 281: 1274-1285.
8. Liu W, Wang S, Wei S, Sun L, Feng X,. 2005. Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. J Biol Chem 280: 43064-43072. (Pubitemid 43049272)
9. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB,. 2000. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 105: 1697-1710. (Pubitemid 30421751)
10. 2+ signaling. J Immunol 175: 917-925. (Pubitemid 41094975)
11. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL,. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105: 433-440. (Pubitemid 30127243)
12. McNally AK, Anderson JM,. 1995. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am J Pathol 147: 1487-1499.
13. Moreno JL, Kaczmarek M, Keegan AD, Tondravi M,. 2003. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. Blood 102: 1078-1086. (Pubitemid 36917809)
14. 2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 231: 241-256.
15. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE,. 1999. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701-738. (Pubitemid 29241138)
16. Rho J, Altmann CR, Socci ND, Merkov L, Kim N, So H, Lee O, Takami M, Brivanlou AH, Choi Y,. 2002. Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell Biol 21: 541-549.
17. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM,. 2003. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821-831. (Pubitemid 37074957)
18. Saidenberg-Kermanac'h N, Bessis N, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal M,. 2004. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J Clin Immunol 24: 370-378. (Pubitemid 39005569)
19. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K,. 2000. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39: 122-132. (Pubitemid 30139344)
20. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N,. 2009. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 583: 2435-2440.
21. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV,. 2007. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 313: 168-178. (Pubitemid 44958461)
22. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T,. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901. (Pubitemid 35460788)
23. Takeshita S, Kaji K, Kudo A,. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15: 1477-1488. (Pubitemid 30484517)
24. Teitelbaum S,. 2005. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther 29: 201.
25. Teitelbaum SL,. 2007. Osteoclasts: What do they do and how do they do it ? Am J Pathol 170: 427-435.
26. Teitelbaum SL, Ross FP,. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649. (Pubitemid 36917505)
27. Walsh NC, Gravallese EM,. 2010. Bone remodeling in rheumatic disease: A question of balance. Immunol Rev 233: 301-312.
28. Wei S, Siegal GP,. 2008. Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets. Pathol Res Pract 204: 695-706.
29. Wei S, Wang MW, Teitelbaum SL, Ross FP,. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 277: 6622-6630. (Pubitemid 34968463)
30. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL,. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115: 282-290. (Pubitemid 40385470)
31. Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Haines GK, Kumar P, Koch AE,. 2001. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 166: 1214-1222. (Pubitemid 32060282)
32. Yu M, Moreno JL, Stains JP, Keegan AD,. 2009. Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly. J Biol Chem 284: 32968-32979.
33. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G,. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50: 277-290. (Pubitemid 38084313)